Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Advances in Genetic Testing: A Focus on Hereditary Cancer

This activity is not available for credits. However, you can listen/view the educational content. Approximately 14 million new cancer cases were di...

Available credits: 0.25

Time to complete: 15 minutes

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This activity is not available for credits. However, you can listen/view the educational content. Approximately 14 million new cancer cases were diagnosed worldwide in a single year, according to recent GLOBOCAN data for 2012. Of these cases, an estimated 3-10% can be considered to be hereditary tumors. Dr. McDonough and Dr. Audeh discuss the genetic basis for hereditary cancer, including how to identify key characteristics, as well as describe the criteria for which genetic testing is considered appropriate. 


  • Disclosure of Conflicts of Interest

    M. William Audeh, M.D., M.S
    Medical Oncology and Cancer Risk Assessment
    Breast Cancer Program – Samuel Oschin Cancer Institute
    Associate Clinical Professor of Medicine, Cedars-Sinai Medical Center and UCLA School of Medicine
    Medical Director, Wasserman Breast Cancer Risk Reduction Program
    Samuel Oschin Cancer Institute at Cedars-Sinai Medical Center
    Los Angeles, CA 
    Brian P. McDonough, MD
    Clinical Professor of Family Medicine
    Temple University School of Medicine
    Philadelphia, PA
    Chairman, Department of Family Medicine
    St. Francis Hospital
    Wilmington, DE 
    Disclosure of Conflicts of Interest:
    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
    The following faculty have reported real or apparent conflicts of interest that have been resolved:
    • Dr. William Audeh is a consultant for Amgen.
    • Dr. Brian McDonough has nothing to disclose.

    The following reviewers/planners/authors have reported real or apparent conflicts of interest that have been resolved:

    • Andy Beloff has nothing to disclose.
    • Emma DelVecchio has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Sean T. Saunders, CCMEP has nothing to disclose.
  • Target Audience

    The target audience for this activity includes Oncologists, Primary Care Physicians and OB/Gyns.

  • Learning Objectives

    After listening to this educational activity, participants should be better able to:
    • Explain the genetic basis for hereditary cancer and describe its key characteristics
    • Describe the criteria for which genetic testing is considered appropriate
    • Identify individuals that warrant referral for further genetic risk evaluation
    • Appreciate the range of genetic tests currently available and how to interpret them in clinical practice
  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    Credit Designation
    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be available for immediate download at 
  • Provider(s)/Educational Partner(s)

    Prova Education designs educational programs based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent educational grant from Invitae.

  • Terms of Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Prova Education nor TOPEC recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Prova Education or TOPEC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Instructions

    There are no fees for participating in and receiving CME credit for this activity. During the period August 21, 2015 through August 21, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) listen to the full content of the activity and reflect upon its teachings; 3) successfully complete the post-test with a passing score and the evaluation at the end of the activity.

    Participants who successfully complete the activity, post-test and evaluation will have a   statement of credit made available immediately.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of ReachMD you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio



    You must be in to display playlists.

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.